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Pharmacy News
‘Warfarin’ – High Alert Medication Policy 
Update
Preamble
Oral anticoagulation with warfarin is a challenging 
task for health care providers around the world. 
Due to narrow therapeutic index and less    predict-
able pharmacokinetics, its use should be abided by 
strict safety measures. These include safe prescrib-
ing, monitoring, patient education and regular fol-
low ups. The important monitoring aspects are 
evaluation for active bleeding, bleeding tenden-
cies and laboratory parameters such as prothrom-
bin time/ international normalized ration.
Our Scenario: Appreciating the potential risk 
to the patients, Pharmacy and Therapeutics 
Committee (P and TC) of AKUH has categorised 
Warfarin as High Alert Medication and developed 
a Prescribing and Monitoring Guideline along with 
Patient’s Guide and Record Book.  
Salient features of the guidelines are given below:
Correct Patient: 
•  Patient should be identified properly with two 
identifiers before prescribing, dispensing and 
administration.
Prescribing and Monitoring:
• Verbal orders are not allowed for Warfarin.
• All the prescribing and monitoring shall be 
guided by the approved guidelines.
• Order shall be complete, correct and include 
all the necessary parameters.
• Baseline INR should be checked before 
ordering and repeated at suitable intervals to 
ensure proper dosing.
• Target INR value is set and known to all care 
providers in order to ensure proper dose 
adjustment and monitoring.
• Proper assessment for side effects is carried 
out (esp. bleeding) at suitable intervals.
• Order should be reviewed every 24 hours or 
upon the availability of recent lab values.
Dispensing and Patient Education: 
• Warfarin will be dispensed from pharmacy 
against a valid physician order.
• Dispensed dose will be labeled properly with 
complete dosing information.
• Medication related education is provided to 
patient/family upon discharge and on OPD
refills to ensure safe use of this drug.
Guidelines Also Mention: 
• need and rationale of loading dose
• maintenance dose and dose adjustments
• target INRs for different indications
• duration of therapy
• common and important drug-to-drug and drug-
food interactions
• reversal before surgery
• risk factors for bleeding
• management of moderate and severe bleeding
• head to toe assessment for side effects
Details are available in High Alert Medications 
Policy (annexure) available at :
http://intranet/pharmacy/pdf/QA018.pdf
Rational use of Antibiotics 2011 –  Snapshot
Preamble
Antibiotic Subcommittee (ABSC) of AKUH has 
selected six broad spectrum and costly 
antibiotics that are considered as the last resort for 
multi-drug resistant microorganisms. Hence, their 
usage is guided by the approved protocol for 
prescribing. Adherence to set criteria is also 
periodically monitored to ensure their rational use.
Six restricted antibiotics are imipenem, 
meropenem, vancomycin, polymyxin B, piperacillin/
tazobactam and linezolid.
Methodology for Drug Utilisation Reviews (DURs)
A representative sample of patients was taken 
who were administered the restricted antibiotics. 
Sample was based on the volume of consump-
tion of antibiotics specialty wise. Each patient was 
assessed against the criteria of restricted antibiotic 
usage, approved by the Antibiotic Subcommittee 
(ABSC) of the Hospital. Results are plotted as either 
compliance or non-compliance to the criteria of the 
usage. The data is presented in the ABSC.
3S# Antibiotic Concern Improvement required in
1. Meropenem • cultures were not sent prior to start of the therapy
• prolonged empiric therapy
 Paediatrics
 Medicine 
2. Imipenem
• cultures were not sent prior to start of the therapy
• based on cultures, on-time de-escalation was not 
carried out
 Surgery
 Medicine  
3. Vancomycin
• cultures were not sent prior to start of the therapy
• on-time de-escalation not done based on C/S
• levels were not monitored properly
 Medicine
 Surgery
 Paediatrics
4. Polymyxin
• empiric polymyxin upon admission
• cultures  were not suggestive of multiple antibiotic 
resistant organisms (MARO)
              Surgery
5.
Piperacillin/
Tazobactam
• cultures were not sent prior to start of the therapy
• duplication with other penicillins
 Emergency
 Surgery 
6. Linezolid
• unclear indication for linezolid, prior infectious dis-
ease approval was not taken
• duplication with vancomycin
             Surgery
Major Non-Compliance to the Approved Criteria of Restricted Antibiotics in Year 2011:
What can you do to help?
Clinicians should focus on the major non-com-
pliance factors and attempts should be made to 
abide the use of restricted antibiotics against the 
approved criteria of the Hospital.
According to the patient safety recommendations 
worldwide and JCIA standards, review of prescrip-
tion by a pharmacist is an important step to prevent 
any medication error at the time of prescribing. It is
For complete information on the prescribing 
and monitoring protocol of these antibiotics, 
faculty and staff can refer to the pocket Antibiotic 
Guideline or the online version at : 
http://intranet/pharmacy/Antibiotic_GL_com-
pletebook.pdf
also a tool to prevent serious medication errors.
The 2011 snapshot of pharmacists’ interventions to 
provide care to a more acceptable level:
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Pharmacist Interventions – Curbing Potential Prescribing Errors
4Source: www.fda.gov 
FDA Safety Updates and Alerts - 2011
Drug Month Updates
Antipsychotics February
Treatment during pregnancy (third trimester) imposes potential 
risk for abnormal muscle movements (extrapyramidal signs or EPS) 
and withdrawal symptoms in newborns.
Proton Pump Inhibitors March Hypomagnesemia can be associated with long-term use.
Topiramate March
Increased risk of development of cleft lip and/or cleft palate (oral 
clefts) in infants of women treated with topiramate during preg-
nancy.
Rosiglitazone April Associated with the risk of cardiovascular events (including heart 
attack and stroke).
Angiotensin Receptor 
Blockers
June
Use of ARBs may be associated with a small increased risk of can-
cer. FDA will provide the information as the review is completed.
Varenicline June
Increased risk of certain cardiovascular adverse events in patients 
who have cardiovascular disease.
Epoetin alfa June
In patients with chronic kidney disease, it increases the risk of seri-
ous cardiovascular events such as heart attack or stroke.
Valproate Product June
Risk of impaired cognitive development in children exposed to val-
proate products In-Utero (during pregnancy).
Simvastatin June
Use of the highest approved dose of simvastatin (80 mg) should be 
limited because of increased risk of myopathy.
Oral Bisphosphonates July
Use of oral bisphosphonate drugs is associated with an increased 
risk of cancer of the esophagus. FDA will provide the update when 
more information is available.
Citalopram August Abnormal heart rhythms are associated with high doses.
Fluconazole August
Use of long-term, high dose fluconazole during pregnancy (first 
trimester) may be associated with birth defects in infants.
Zoledronic acid September
It is contraindicated in patients with creatinine clearance less than 
35 ml/min or in patients with evidence of acute renal impairment.
Ondansetron September
Ondansetron may increase the risk of abnormal heart rhythm, 
including torsade de pointes.
Methylene Blue October
Serious CNS reactions are reported when it is given with psychiatric 
medications that interfere the serotonin system of the brain.
Linezolid October
Serious CNS reactions are reported when it is given with psychiatric 
medications that interfere the serotonin system of the brain.
SSRIs’ December
Has potential risk of persistent pulmonary hypertension of the 
newborn when used during pregnancy.
Reporting Adverse Drug Reactions:
Literature suggests that Adverse Drug Reactions 
(ADRs) account for 4-6 per cent  morbidity and 
0.15 per cent mortality in a given population. It is 
important for patient safety perspective to identify 
and report the ADRs. To report an ADR, browse the 
online ADR reporting form; 
http://intranet/pharmacy/adrrf.htm
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